The University of Oxford receives its first batch of AZD1222, a coronavirus vaccine candidate.
Academics at the Jenner Institute at the University of Oxford, UK, have received 4000
doses of AZD1222 (formerly known as ChAdOx1 nCoV-19) for use in a Phase 2/3
trial from Italian contract manufacturer Advent, part of the IRBM Group.
Credit: Advent, IRBM
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine